- Home
- INCR vs ASRT Comparison
INCR vs ASRT Comparison
Compare INCR & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- ASRT
- Stock Information
- Founded
- INCR 1994
- ASRT 1995
- Country
- INCR Israel
- ASRT United States
- Employees
- INCR N/A
- ASRT N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- INCR Health Care
- ASRT Health Care
- Exchange
- INCR Nasdaq
- ASRT Nasdaq
- Market Cap
- INCR 76.7M
- ASRT 78.3M
- IPO Year
- INCR N/A
- ASRT 1997
- Fundamental
- Price
- INCR $1.38
- ASRT $0.67
- Analyst Decision
- INCR
- ASRT Strong Buy
- Analyst Count
- INCR 0
- ASRT 3
- Target Price
- INCR N/A
- ASRT $3.08
- AVG Volume (30 Days)
- INCR 15.9K
- ASRT 419.7K
- Earning Date
- INCR 04-08-2025
- ASRT 03-12-2025
- Dividend Yield
- INCR N/A
- ASRT N/A
- EPS Growth
- INCR N/A
- ASRT N/A
- EPS
- INCR N/A
- ASRT N/A
- Revenue
- INCR $72,420,918.00
- ASRT $124,961,000.00
- Revenue This Year
- INCR N/A
- ASRT $0.96
- Revenue Next Year
- INCR $39.30
- ASRT $12.72
- P/E Ratio
- INCR N/A
- ASRT N/A
- Revenue Growth
- INCR N/A
- ASRT N/A
- 52 Week Low
- INCR $1.17
- ASRT $0.67
- 52 Week High
- INCR $3.72
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- INCR 28.72
- ASRT 33.74
- Support Level
- INCR $1.37
- ASRT $0.70
- Resistance Level
- INCR $1.49
- ASRT $0.75
- Average True Range (ATR)
- INCR 0.06
- ASRT 0.05
- MACD
- INCR -0.02
- ASRT -0.00
- Stochastic Oscillator
- INCR 3.98
- ASRT 3.02
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.